Routine clinical use of biomaterials requires to foster their production. This implies the reduction of their economical and ethical costs. Our aim is to act on the biocompatibility tests (ISO10993-6 EU norm) which are unsustainable for small-medium industries and for the society.
In this project we foster an unprecedented breakthrough in in-vivo optical imaging that will radically renew the biocompatibility tests of biomaterials.
This is based on the combination of three pillars:
1. 2-photon fabrication of microlenses and microstructures to visualize and host biomaterial specimens.
2. non-linear excitation microscopy in-vivo through the micro-lenses.
3. numerical simulations of the immune response to the biomaterials.